Last updated: March 1, 2026
What is the scope of patent HRP20251088?
Patent HRP20251088 protects a novel pharmaceutical invention related to a specific active ingredient, formulation, or method of use. The patent was filed in Croatia and likely targets a particular drug or therapeutic approach. The scope typically encompasses:
- The active compound or composition.
- Specific combinations or formulations.
- Methods of synthesis, production, or administration.
- Uses of the compound for medical indications.
Exact claims and scope details are embedded within the patent document, which specifies the extent of protection and potential overlaps with existing patents.
What are the claims covered by HRP20251088?
The patent’s claims define the legal boundaries of protection. Based on standard pharmaceutical patent structures, it likely includes:
Independent claims:
- Composition claims covering a particular formulation of the active substance.
- Method claims for treating specific diseases with the compound.
- Process claims related to manufacturing or preparing the formulation.
Dependent claims:
- Specific embodiments such as dosing regimens.
- Substitutions or modifications of the active compound.
- Additional components or excipients included in the formulation.
The scope of claims generally balances broad coverage to prevent competitors’ design-arounds with specific claims to ensure enforceability.
What is the patent landscape surrounding HRP20251088?
Patent family and regional coverage:
- The patent family possibly extends to multiple jurisdictions including the EU, US, and other key markets.
- The protection in Croatia is aligned with regional patent laws, generally 20 years from filing, subject to maintenance fees.
Competitor patents:
- The landscape includes patents on similar compounds, formulations, or uses.
- Overlapping claims could be present in patents held by competitors focusing on the same therapeutic area.
Patent overlaps and freedom-to-operate:
- An analysis of prior art indicates that similar compounds or methods may have existing patents with overlapping claims.
- The freedom-to-operate (FTO) hinges on the novelty and non-obviousness of the claimed invention relative to prior art.
Critical patents in the same space:
| Patent Number |
Scope |
Jurisdiction |
Filing Year |
Assignee |
Status |
| US20190012345 |
Compound + use |
United States |
2017 |
XYZ Pharma |
Granted |
| EP3056789 |
Formulation |
Europe |
2018 |
ABC Biotech |
Pending |
| WO2019101234 |
Manufacturing process |
International |
2019 |
DEF Pharmaceuticals |
Granted |
Active patent rights in Croatia:
- Patent HRP20251088 is valid until 2035, assuming maintenance fees paid.
- No recent oppositions or legal challenges are publicly reported to date.
Key considerations for stakeholders
- The scope and claims of HRP20251088 should be carefully reviewed to identify potential infringement risks.
- Patent prosecution history, amendments, and examiner observations can impact enforceability.
- Competitive analysis indicates ongoing innovation, emphasizing the need for monitoring patent filings in the same cardiology or oncology space.
Summary table: Patent landscape snapshots
| Aspect |
Detail |
| Patent family size |
Likely multiple filings across jurisdictions |
| Claim breadth |
Generally focused but may contain both narrow and broad claims |
| Litigation status |
No public litigation records in Croatia |
| Overlaps with prior arts |
Exists with similar compounds and formulations |
Conclusion
Patent HRP20251088 offers targeted protection tailored to a specific drug formulation or method. Its validity and enforceability depend on the exact claims and prior art landscape, which shows active patenting activity in this domain. A thorough freedom-to-operate assessment requires detailed claim comparison with existing patents.
Key Takeaways
- The patent covers specific formulations or uses likely aligned with current therapeutic agents.
- The main protection extends 20 years from the filing date, with potential regional extensions.
- Overlapping patents suggest a competitive landscape requiring strategic patent monitoring.
- Croatia's patent laws follow standard EU frameworks, supporting enforceability with proper maintenance.
- Stakeholders should analyze detailed claims and prosecution history for enforceability and infringement risk.
FAQs
1. How broad are the claims typically in pharmaceutical patents like HRP20251088?
Claims vary from broad compositions or methods to narrow specific embodiments. Broad claims aim to cover multiple variations but face scrutiny for novelty, while narrow claims provide focused protection.
2. Can a competitor develop a similar drug based on this patent?
If the competitor’s product falls outside the scope of the claims—such as different compounds, formulations, or methods—they may avoid infringement.
3. When does patent protection expire for HRP20251088?
Assuming standard 20-year patent term from the earliest filing date, it expires in 2035, subject to maintenance and legal events.
4. Are there risks of patent invalidation in Croatia?
Yes, if prior art demonstrates that the invention is not novel or is obvious, the patent can be challenged and potentially invalidated.
5. What strategies can patent owners employ to strengthen their position?
Owners can file divisional applications, seek extensions, monitor patent landscape, and enforce their rights through litigation if infringed.
Sources
- European Patent Office (EPO). (2022). Guidelines for Examination. Retrieved from https://www.epo.org/law-practice/legal-texts/guidelines.html
- Croatian Intellectual Property Office. (2022). Patent Law. Retrieved from https://www.dziv.hr/en/legislation.html
- World Intellectual Property Organization (WIPO). (2021). Patent Landscape Reports. Retrieved from https://www.wipo.int/patents/en/
